Introduction:-

Leigh Syndrome (LS) is a rare, severe neurological disorder that typically manifests in infancy or early childhood. It is primarily caused by mitochondrial dysfunction, which results in progressive neurodegeneration. This condition affects approximately 1 in 40,000 newborns and is characterized by lesions in the brainstem and basal ganglia, leading to motor and cognitive impairments.

Pathophysiology of Leigh Syndrome

Mitochondrial dysfunction is central to the pathology of Leigh Syndrome. The mitochondria, often referred to as the powerhouse of the cell, generate adenosine triphosphate (ATP) through oxidative phosphorylation (OXPHOS). This process occurs within the electron transport chain (ETC), which consists of five protein complexes embedded in the inner mitochondrial membrane. In LS, genetic mutations disrupt these complexes, impairing ATP production and causing an accumulation of toxic byproducts such as reactive oxygen species (ROS) and lactate.

The most frequently affected complexes in Leigh Syndrome are Complex I (NADH: ubiquinone oxidoreductase) and Complex IV (cytochrome c oxidase). Mutations in nuclear or mitochondrial DNA (mtDNA) encoding subunits of these complexes lead to decreased enzymatic activity, impairing energy production. As neurons have high energy demands, they are particularly vulnerable to mitochondrial defects, resulting in neuronal cell death and progressive neurodegeneration.

Genetic and Biochemical Basis

Leigh Syndrome is genetically heterogeneous, with over 75 known causative genes. Mutations can be inherited in an autosomal recessive, X-linked, or maternal manner, depending on whether the affected gene is in nuclear DNA or mtDNA. Some of the most common mutations occur in:

MT-ND genes (affecting Complex I)
SURF1 gene (associated with Complex IV deficiency)
PDHA1 gene (disrupting pyruvate dehydrogenase complex, leading to lactic acidosis)

Mitochondrial DNA mutations are maternally inherited, while nuclear DNA mutations follow Mendelian inheritance patterns. The variability in genetic origins contributes to the clinical heterogeneity observed in Leigh Syndrome.

Impact on the Nervous System

Mitochondrial dysfunction in LS predominantly affects the central nervous system (CNS), leading to hallmark neuropathological changes. Bilateral symmetrical lesions appear in the basal ganglia, thalamus, cerebellum, and brainstem. These lesions result from energy deficits and ROS-induced damage, leading to demyelination, gliosis, and neuronal loss.

The neurological symptoms of Leigh Syndrome include:

Developmental delay and regression
Hypotonia (low muscle tone)
Dystonia (involuntary muscle contractions)
Ataxia (lack of muscle coordination)
Ophthalmoplegia (paralysis of eye muscles)
Respiratory failure due to brainstem involvement

As the disease progresses, affected individuals experience worsening motor and cognitive impairments, ultimately leading to severe disability and premature death.

Systemic Effects Beyond the CNS

While Leigh Syndrome primarily affects the nervous system, mitochondrial dysfunction also impacts other organ systems. Metabolic abnormalities such as lactic acidosis arise due to impaired oxidative metabolism, leading to energy deficits in multiple tissues. Additionally, cardiac involvement, such as hypertrophic cardiomyopathy, has been observed in some cases, reflecting the high energy demands of the heart.

The gastrointestinal system may also be affected, with symptoms such as feeding difficulties, failure to thrive, and gastrointestinal dysmotility. This further complicates disease management and contributes to the overall severity of the condition.

Conclusion

Leigh Syndrome is a devastating disorder driven by mitochondrial dysfunction, resulting in widespread neurodegeneration and multi-organ involvement. The genetic heterogeneity and complexity of mitochondrial pathology make it a challenging condition to study and manage. Understanding the molecular basis of mitochondrial dysfunction in LS provides crucial insights into the disease mechanism and potential therapeutic avenues, though treatment remains limited. Continued research into mitochondrial bioenergetics and genetic contributions will be essential in advancing our knowledge of Leigh Syndrome and related mitochondrial disorders.

https://www.blueoaknx.com/

Mitochondrial Dysfunction in Leigh Syndrome